Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3345 | Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP Wiki | 0.71 |
| drug258 | AirGo Respiratory Monitor Wiki | 0.71 |
| drug1339 | Direct laryngoscope Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.05 |
| D011014 | Pneumonia NIH | 0.04 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002791 | Hypoventilation HPO | 1.00 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 2 clinical trials
This study uses the AirGo band to monitor changes in tidal ventilation in spontaneously breathing patients with COVID-19 associated respiratory failure. It aims to recognize patterns of ventilation associated with worsening respiratory failure in this patient population. If successful, this study will lead to the development of new robust methods for real-time, continuous monitoring of respiratory function in patients with respiratory failure. In turn, such monitoring methods may enable improvements in the medical management of respiratory failure and timing of interventions.
Description: Progression of respiratory failure to require endotracheal intubation (and mechanical ventilation)
Measure: Endotracheal intubation during present hospitalization, recorded through chart review Time: Up to three weeksDescription: Maintenance of SpO2 >=90% on no or low flow supplemental oxygen (=< 1 liter by nasal cannula or CPAP, or return of supplemental oxygen to baseline if required supplemental O2 for another indication, prior to onset of COVID-19 infection)
Measure: Improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review Time: Up to three weeksDescription: Patient or care provider may request removal of the band for any reason prior to the patient reaching the outcome
Measure: Premature need for removal of the band, recorded through investigator report Time: Up to three weeksDescription: Death from any cause while in the hospital
Measure: In-hospital mortality, recorded through chart review Time: Up to 24 weeksVarious guidelines for endotracheal intubation (insertion of breathing tube for mechanical ventilation) of Coronavirus Disease 2019 (COVID-19) patients recommend the use of videolaryngoscope (medical device used for intubation that has a camera to visualize the vocal cords between which the breathing tube will pass) over direct laryngoscope (conventionally-used medical device for intubation that depends on anesthetist's direct visualization of vocal cords). The reasons for this recommendation are to maximize the distance between the medical personnel and the patient's face during intubation to decrease the risk of viral particles transmission and to improve intubation success. For patients infected with COVID-19, Powered Air Purifying Respirator (PAPR) is recommended as an alternative to N95 masks during aerosol-generating procedures such as intubation because N95 masks may not fully protect medical personnel from viral transmission during intubation. There is no evidence to suggest that videolaryngoscope (VL) is superior to direct laryngoscope (DL) for intubation when PAPR is donned. The purpose of this study is to determine if McGrath VL is superior to DL for intubation when the anesthetist is wearing a PAPR. The investigators' hypothesis is that McGrath VL will decrease the time to intubation by 20 seconds and more compared to DL when PAPR is donned. The investigators also hope to learn if there is any difference in the difficulties encountered between the use of VL and DL.
Description: The time to intubation starts from the time the anesthetist takes over the laryngoscope till the first appearance of consecutive capnography tracings. The time to intubation will be assessed via a retrospective playback of the video-recording of the intubation process. Compares the time to intubation for McGrath videolaryngoscope against direct laryngoscope.
Measure: Time to intubation for McGrath videolaryngoscope versus direct laryngoscope Time: During the intubation processDescription: Compares the incidence of success at first intubation attempt using McGrath videolaryngoscope against direct laryngoscope. To be assessed via a retrospective playback of the video-recording of the intubation process.
Measure: Incidence of success at first intubation attempt with McGrath videolaryngoscope versus direct laryngoscope Time: During the intubation processDescription: Compares the incidence of the use of adjuncts (bougie, stylet, external laryngeal pressure, hyper-angulated blades) at first attempt with McGrath videolaryngoscope against direct laryngoscope. To be assessed via a retrospective playback of the video-recording of the intubation process
Measure: Incidence of the use of adjuncts at first attempt with McGrath videolaryngoscope versus direct laryngoscope Time: During the intubation processDescription: Compares the incidence of the use of adjuncts (bougie, stylet, external laryngeal pressure, hyper-angulated blades) at subsequent attempts (after first attempt) with McGrath videolaryngoscope against direct laryngoscope. To be assessed via a retrospective playback of the video-recording of the intubation process
Measure: Incidence of the use of adjuncts at subsequent attempts with McGrath videolaryngoscope versus direct laryngoscope Time: During the intubation processDescription: Compares the incidence of success and failure at intubation using the initial laryngoscope that the anesthetist is randomised to. To be assessed via a retrospective playback of the video-recording of the intubation process.
Measure: Incidence of success and failure at intubation using initial laryngoscope Time: During the intubation processDescription: Compares the Intubation Difficulty Scale between using McGrath videolaryngoscope and direct laryngoscope for intubation. The scale is the sum of score from 7 variables. Ranges from 0 ("ideal" intubation, that is one performed without effort, on the first attempt, practiced by one operator, using one technique, full visualization of laryngeal aperture and vocal cords abducted) to infinity (impossible intubation). The higher the scale, the more difficulty the intubation process. To be assessed via a retrospective playback of the video-recording of the intubation process and also by interviewing the anesthetist who carried out the intubation.
Measure: Intubation Difficulty Scale with McGrath videolaryngoscope versus direct laryngoscope Time: During the intubation processDescription: Compares the incidence of oxygen desaturation to less than 88% and oro-dental injuries between the McGrath videolaryngoscope and direct laryngoscope. To be assessed during the playback of the video-recording of the intubation process and by interviewing the anesthetist.
Measure: Incidence of oxygen desaturation to less than 88% and oro-dental injuries with McGrath videolaryngoscope versus direct laryngoscope. Time: During the intubation process.Description: Compares the incidence of inability to intubate despite all efforts by the anesthetist between the McGrath videolaryngoscope and the direct laryngoscope. To be assessed during the playback of the video-recording of the intubation process.
Measure: Incidence of inability to intubate despite all efforts by the anesthetist with McGrath videolaryngoscope versus direct laryngoscope Time: During the intubation processAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports